Jordan Gauthier, Associate Professor at Fred Hutch and the University of Washington, shared a post on LinkedIn:
“I’m delighted to share two presentations from our group at ASH 2025, focused on improving the safety of CAR T-cell therapy.
Oral Presentation — High-dose anakinra for refractory ICANS
Abstract 928
Presenter: Emily Liang, MD
Date: Monday, December 8, 2:45 PM – 4:15 PM EST
Location: OCCC – Sunburst Room (W340)
Key findings:
- Comprehensive benchmarking of outcomes in the largest cohort to date (N = 101), conducted in collaboration with Oregon Health and Science University.
- Median ICANS resolution: 8 days.
- Significant neurologic improvement (≥2-grade ICANS reduction without additional ICANS-directed therapy) achieved in 44% of patients at 72 hours.
- Anti-tumor efficacy preserved (91% CR/PR at day +28).
- Identified potential point-of-care biomarkers associated with anakinra efficacy, including platelet count, ferritin, and fibrinogen.
Abstract 4147
Presenter: Yein Jeon, MSc
Date: Sunday, December 7, 6:00 PM – 8:00 PM EST
Location: OCCC – West Halls B3–B4
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities — Poster II
Key findings:
- Commonly used ALC thresholds (3,000 and 5,000/µL) demonstrated limited discrimination, with high false-positive rates and meaningful false-negative rates.
- Findings support the need to move beyond single-parameter thresholds for pre-emptive management.
- Introduced a new prognostic model — NEMO — integrating point-of-care variables beyond ALC (CRP, fibrinogen, platelets). NEMO outperforms ALC-only approaches.
- Additional analyses will be presented as an oral presentation at Annual Tandem Meeting of the ASTCT and CIBMTR in February 2026!”
More posts featuring Jordan Gauthier.